Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04517760
Other study ID # EG0216
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 22, 2018
Est. completion date September 30, 2019

Study information

Verified date August 2020
Source Elizabeth Glaser Pediatric AIDS Foundation
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of the research was to evaluate the performance of items within the Kizazi Kipya (K2) Orphan and Vulnerable Children (OVC) HIV risk screening tool in identifying HIV-positive children, to optimize an HIV screening tool for OVC and children and adolescents in facility settings and to assess the feasibility and acceptability of home-based HIV risk screening and testing.


Description:

Under the ongoing community-based Kizazi Kipya (K2) OVC project, program staff currently administer a 13-item HIV risk screening tool to all K2 program beneficiaries, and refers those who screen positive to facility-based HIV testing. A subset of this 13-item tool is a module of four items that had previously been used as a standalone four-question screening tool in facilities in Zimbabwe.

The primary objectives of this study are as follows.

1. To evaluate the performance of a lay cadre-administered four-item subset of the K2 HIV risk screening tool that matches the Zimbabwe evidence-based tool in predicting the HIV status of vulnerable children/adolescents represented by two populations: (a) K2 OVC beneficiaries and (b) children/adolescents attending health facilities.

2. To identify additional items in the K2 HIV risk screening tool that could be added to the four-question subset to improve the tool's performance.

3. To assess fidelity to the administration of the OVC HIV screening tool items through structured observations of community case workers in the K2 program.

4. To assess the acceptability of OVC HIV risk screening and testing implemented in the community among OVC beneficiaries in the K2 program.

5. To assess the acceptability and feasibility of integrating the OVC HIV screening tool with HIV testing among OVC community case workers in the K2 program.


Recruitment information / eligibility

Status Completed
Enrollment 21080
Est. completion date September 30, 2019
Est. primary completion date September 30, 2019
Accepts healthy volunteers No
Gender All
Age group 2 Years to 19 Years
Eligibility Children and adolescents and their caregivers:

Inclusion Criteria:

- Living in a household deemed to be at elevated HIV risk based on previously identified risk criteria

- Attending a study health facility in two regions of Tanzania

- Age 2-19 years

Exclusion Criteria:

- Previously tested HIV-positive

- History of antiretroviral treatment (ART)

- Unable or unwilling to be consented

- Age 5-19 years old, tested negative in past 6 months, and having no reported exposure to HIV through sexual contact (consensual, abuse) or through blood transfusion/needle injury.

Community care workers:

Inclusion criteria:

- conducting HIV risk screening in OVC households as part of their role in the Kizazi Kipya project in the subset of study districts where structured observations and focus group discussions were conducted

Exclusion criteria:

- unwilling to consent to the study

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Tanzania Elizabeth Glaser Pediatric AIDS Foundation Dar es Salaam

Sponsors (3)

Lead Sponsor Collaborator
Elizabeth Glaser Pediatric AIDS Foundation PACT International, Tanzania Ministry of Health, Community Development, Gender, Elderly and Children

Country where clinical trial is conducted

Tanzania, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sensitivity of HIV risk screening tool Children/adolescents testing HIV positive on the tool who are truly HIV positive Within four weeks
Primary Specificity of HIV risk screening tool Children/adolescents testing HIV negative on the tool who are truly HIV negative Within four weeks
Primary Positive predictive value Proportion of children/adolescents testing positive on the tool who actually have HIV Within four weeks
Primary Negative predictive value Proportion of children/adolescents testing negative on the tool who do not actually have HIV Within four weeks
Primary Acceptability of HIV risk screening tool Examining the extent of reception of the screening tool by the OVC caregivers and the community case workers using a semi-structured questionnaire Within six weeks
Primary Feasibility of HIV risk screening tool Exploring the practicality of use of HIV risk screening tool through focus group discussions with community case workers Within six weeks
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06281834 - Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention Phase 1
Completed NCT04206878 - Evaluating the Feasibility of Point of Care Birth Testing in Eswatini
Recruiting NCT05069688 - Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin Phase 1
Active, not recruiting NCT03024762 - Active Search for Pediatric HIV/AIDS (ASPA) N/A
Recruiting NCT05006170 - Pharmacokinetics, Safety, and Efficacy of Dolutegravir Dispersible Tablets in Young Children Living With HIV Phase 2
Not yet recruiting NCT03980119 - Utilizing the HITSystem for Optimizing Paediatric ART Retention and Adherence in Western Nyanza Province, Kenya N/A
Completed NCT03824067 - Impact of Point-of-Care EID for HIV-Exposed Infants N/A